Merck phase i pipeline. Candidates shown in Phase 3 include specific products.

Merck phase i pipeline Candidates shown in Healthcare pipeline Phase 1 Phase 2 Phase 3 Registration pimicotinib (CSF-1R inhibitor) Tenosynovial giant cell tumor (TGCT)1,2 BASKING RIDGE, N. 3 million people acquired HIV in 2023, highlighting the continued need for new PrEP options like our investigational once Our pipeline features groundbreaking therapies in development to address anxiety, PTSD, and other neuropsychiatric disorders. Candidates shown in Phase 3 include specific products. Jul 14, 2025 · FDA accepts New Drug Application for Merck’s doravirine/islatravir (DOR/ISL) HIV regimen: The once-daily, oral, two Dec 18, 2024 · Three months after Merck & Co opted in to a new Kelun-derived ADC, MK-2750/SKB571, the molecule is formally starting phase Aug 12, 2025 · Merck (MRK) recently announced positive topline results from its Phase 3 KEYNOTE-905 trial, showcasing efficacy for KEYTRUDA in patients with muscle-invasive May 21, 2025 · Merck Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with CLE and Dec 17, 2024 · Source: OncologyPipeline & clinicaltrials. It can take more than 10 years to bring a new medicine to market. Find out what makes CD388 a potential flu game-changer. Candidates The chart reflects the Merck research pipeline as of April 30, 2025. -- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and EyeBio, a Candidates shown in Phase 3 include specific products and the date such candidate entered into Phase 3 development. Pallavi Madhiraju Merck Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Phase 2 Study of MK-2060 Currently Ongoing in People with End-Stage Renal Disease Receiving Hemodialysis Merck, (NYSE: MRK), Pipeline We are a clinical-stage immunotherapy company targeting complementary mechanisms to fight cancer, including checkpoint inhibitors, immune activators, and tumor RAHWAY, N. , an OPKO Health company (NASDAQ: OPK), announces dosing of the first participant in the Phase I Merck Pipeline Q4 2023 Reflecting Pipeline to November 1, 2023 Lead-in language The chart below reflects the company’s research pipeline as of November 1, 2023. , & Rahway, N. The chart reflects the Merck research pipeline as of Feb 21, 2025. 2B to expand into long-acting antivirals. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval Merck, known as MSD outside of the US and Canada, a premier research-intensive biopharmaceutical company, is initiating two Phase 2 clinical studies for MK-2214 and MK In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally Merck Explore Merck Healthcare KGaA with its drug pipeline, therapeutic area, technology platform, 78 clinical trials, 12 news, and 29 literature, Disease Domain:Neoplasms, Nervous New and updated data for MK-1084, an investigational KRAS G12C inhibitor, from the colorectal cancer and non-small cell lung cancer cohorts of the Phase 1 KANDLELIT-001 Sotatercept is in phase 3 testing as an add-on therapy for PAH, and according to Merck has the potential to become a $3 billion product Merck is actively redirecting $3 billion from its less profitable segments into high-potential pipeline opportunities, reflecting its strategic Merck faces a looming challenge with the 2028 patent expiration of Keytruda, but it’s not sitting around twiddling test tubes. 2 billion and adding CD388, a late-phase, long-acting antiviral for seasonal influenza prevention Merck KGaA’s oncology attempts haven’t always gone well recently, but on Tuesday the group announced a late-stage victory for pimicotinib, a CSF-1R inhibitor licensed “According to UNAIDS, 1. 8bn acquisition of VelosBio in 2020. J. CD388, in Phase 3 trials, has FDA Merck KGaA, a science and technology leader, is expanding its oncology pipeline with promising new treatments. has agreed to acquire Cidara Therapeutics for approximately $9. 75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate Merck, a leading science and technology company, today announced the first patient has been dosed in the Phase III MyClad trial At Merck, we follow the science. Candidates shown in Phase 2 include the most advanced compound Merck & Co. , an OPKO Health company (NASDAQ: OPK), Merck is acquiring Cidara Therapeutics for $9. A snapshot of the Checkpoint In a significant development in the biopharmaceutical industry, Merck & Co. Candidates shown in Phase 3 Merck today announced new research from the company’s diverse oncology portfolio will be presented at the 2024 ASCO Annual Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor MSD Pipeline Q1 2023 Reflecting Pipeline to February 17, 2023 Lead-in language The chart below reflects the company’s research pipeline as of February 17, 2023. While this pipeline chart remains on the company’s website the company assumes no duty to update the information to reflect subsequent developments. Learn about new candidates and recent acquisitions bolstering their R&D. Candidates 2 days ago · Merck & Co/MSD has agreed to buy Pandion for $1. Candidates shown in Phase 2 include the most advanced compound October 1, 2024 6:45 am EDT Addition of CN201, a next generation CD3xCD19 bispecific antibody with potential applications in B-cell Merck Pipeline Q1 2024 Reflecting Pipeline to February 23, 2024 Lead-in language The chart below reflects the company’s research pipeline as of February 23, 2024. Our mRNA pipeline shows the progress we’re making on clinical programs currently in development to create mRNA medicines for a wide range of MSD has stopped development of anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, blowing a hole in its DelveInsight’s “NSCLC Pipeline Insight 2025” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in the NSCLC pipeline landscape. Candidates shown in Phase 2 include the most advanced compound Merck’s move came after a “routine evaluation” of its pipeline, the spokesperson said, while Biond also pointed to Sanofi’s R&D prioritisation, adding that the phase 1 portion of Find out what drugs does Merck have in the pipeline, with a focus on oncology, HIV, and immunology. gov. Candidates shown in Phase 2 include the most advanced compound “This agreement adds to Merck’s growing oncology pipeline and we look forward to advancing LM-299 with speed and rigor for The chart reflects the MSD research pipeline as of Nov 1, 2024. The CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B BASKING RIDGE, N. , Inc. Candidates shown in Phase 3 First Phase 3 survival data from KEYNOTE-A39/EV-302 support potential benefit of combination approach in previously untreated Merck & Co. 07, 2025 (GLOBE NEWSWIRE) — ModeX Therapeutics Inc. Get a glimpse of how we work to improve lives. Merck Pipeline Q2 2024 Reflecting Pipeline to May 1, 2024 Lead-in language The chart below reflects the company’s research pipeline as of May 1, 2024. At IAS The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing New and updated data for MK-1084, an investigational KRAS G12C inhibitor, from the colorectal cancer and non-small cell lung cancer cohorts of the Phase 1 KANDLELIT-001 Explore Merck Sharp & Dohme LLC with its drug pipeline, therapeutic area, technology platform, 839 clinical trials, 169 news, and Agreement builds on and complements Daiichi Sankyo and Merck’s shared commitment to develop novel medicines for patients with We would like to show you a description here but the site won’t allow us. Dean Y. New York, USA, July 23, 2024 (GLOBE NEWSWIRE) -- GLP Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Merck agreed to buy Cidara for $221. 2 billion focuses on CD388, a promising antiviral for influenza prevention. , an OPKO Health company (NASDAQ: OPK), Dr. The chart reflects the company research pipeline as of November 3, 2025. These data and our work on the longer-acting islatravir-based therapies in our Explore Merck Sharp & Dohme LLC with its drug pipeline, therapeutic area, technology platform, 839 clinical trials, 169 news, and WESTON, Mass. View the Merck pipeline and research, including Merck clinical trials and the Merck Investigator Studies Program (MISP). Candidates shown in Phase 2 include the most advanced compound Sprifermin - Fibroblast Growth Factor 18 Osteoarthritis An investigational Human recombinant FGF18, a protein thought to induce chondrocyte stimulation leading to matrix synthesis and RAHWAY, N. Each program Even beyond Keytruda, Davis has diversified Merck’s pipeline by tripling over the last three years the number of drug candidates in late CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B On Tuesday, 10 June 2025, Merck & Company Inc (NYSE:MRK) presented at the Goldman Sachs 46th Annual Global Healthcare Conference 2025, Our mRNA pipeline shows the progress we’re making on clinical programs currently in development to create mRNA medicines for a wide range of Merck & Co has been relatively quiet about zilovertamab vedotin, the ROR1-targeting ADC it gained through the $2. 3 million people acquired HIV in 2023, highlighting the continued need for new PrEP options like our investigational once CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk of influenza Merck’s move came after a “routine evaluation” of its pipeline, the spokesperson said, while Biond also pointed to Sanofi’s R&D prioritisation, adding that the phase 1 portion of Explore Merck Healthcare KGaA with its drug pipeline, therapeutic area, technology platform, 78 clinical trials, 12 news, and 29 literature, Disease Domain:Neoplasms, Nervous First breakthrough therapy designation for investigational sac-TMT in the U. Merck (NYSE: MRK), known as MSD outside of the The chart reflects the Merck research pipeline as of Aug 2, 2024. Candidates shown in At Merck, we're following the science to tackle some of the world's greatest health threats. Addition of CN201, a next generation CD3xCD19 bispecific antibody with potential applications in B-cell malignancies and autoimmune diseases, broadens and fortifies Merck’s We would like to show you a description here but the site won’t allow us. , Rahway, NJ, USA to co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, Merck’s move came after a “routine evaluation” of its pipeline, the spokesperson said, while Biond also pointed to Sanofi’s R&D prioritisation, adding that the phase 1 portion of Merck & Co. It Moderna, an mRNA specialist known for its COVID-19 vaccine Spikevax, is winding down development of three clinical mRNA programs, including two investigational vaccines for That was based on phase 2 data, and by the time the issues are rectified the project will likely have yielded full data from the phase 3 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided updates on two Phase 3 trials, “We continue to execute our science-led business development strategy, augmenting our pipeline with CD388, a potentially first-in-class, long-acting antiviral designed Merck & Co. Merck Strengthens Oncology Portfolio Through Commercialization Agreement With Abbisko for Phase III Asset, Merck announced the release of positive results from two pivotal Phase 3 trials of the investigational, once-daily, oral, two-drug The chart reflects the Merck research pipeline as of Aug 1, 2025. -- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 – Novel Investigational Combination Regimen is Advancing to Phase 3 and has the Potential to Become the First Weekly Oral HIV Treatment – Foster City, Calif. Candidates shown in Phase 2 include the most advanced compound RAHWAY, N. , September 7, 2024 – Results from an interim analysis of the dose-optimization part of the Merck said it plans to advanced MK-0616 into phase 3 trials before the end of this year, looking at both its ability to reduce LDL Explore Merck's latest developments: Keytruda's expanded FDA approval, promising oncology and vaccine pipeline, and strategic The pipeline page on Gilead’s website also lists two other LA drugs as being in phase I trials: GS-4182, a capsid inhibitor, and GS-1614, a prodrug of Merck’s islatravir being developed A Merck-sponsored phase 3 in relapsed metastatic castrate-resistant prostate cancer will start next month, according to a recent Ph1a Neurology Immunology Oncology Global Health Asset entering new phase5 Current phase Ph1a: phase 1a, dose finding; Ph1b: phase 1b, dose escalation/expansion and signal seeking Merck, a leading science and technology company, today shared updates on the company’s oncology pipeline and focused First breakthrough therapy designation for investigational sac-TMT in the U. Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Jiangsu Hengrui Pharmaceuticals Co. The company plans to initiate Collaboration combines Daiichi Sankyo’s proven ADC expertise and DXd technology with Merck’s deep experience in oncology mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA® (pembrolizumab), Receives PRIME Scheme Designation from The drug is currently in a Phase II clinical trial for the treatment of Stage IV pancreatic cancer. Merck (NYSE: MRK), known as MSD outside of the Merck is actively redirecting $3 billion from its less profitable segments into high-potential pipeline opportunities, reflecting its strategic Merck has been a research pioneer in HIV for decades. The information contained in this chart was current as of November 3, 2025. S. 5M, boots out another asset as pipeline tinkering continues By Nick Paul Taylor Aug 20, Key data from Merck’s portfolio and pipeline to be presented during IDWeek 2024: First time data from the Phase 2b/3 study evaluating a single dose of clesrovimab (MK-1654) The table below is a review of notable updates that occurred in January 2025 for investigational products in development. Learn about Merck's research and products by getting to know the science, strategy and Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate Collaboration to develop, Merck stands at the forefront of research to help prevent and treat diseases that threaten people’s health, by conducting clinical trials Clinical Study / Clesrovimab met all primary safety and efficacy endpoints Merck (NYSE: MRK), known as MSD outside of the United States and Expansion of the waveLINE clinical development program demonstrates company’s progress in advancing research in hematologic Merck is ending development of anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, both of which are in In conclusion, Merck's participation in the TD Cowen 45th Annual Health Care Conference is a critical step in shaping the company's strategic direction and pipeline Another major component of Merck’s HIV pipeline is the once-weekly oral regimen combining islatravir and ulonivirine (ISL/ULO). Closing is expected in H2 2017, subject to regulatory approvals and other conditions. Candidates Zilovertamab vedotin and sacituzumab tirumotecan data to highlight progress in Merck’s pipeline of innovative antibody-drug conjugates. , August 1, 2024 – Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD Additional progress in our pipeline in 2023 includes completion of Phase Ia for our anti-CEACAM5 antibody-drug conjugate (ADC), M9140, with the identification of two doses for Advancing HIV Research At Merck, we are building on our legacy of invention by advancing HIV treatment and prevention options based on the nucleoside reverse transcriptase translocation The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in Merck KGaA, Darmstadt, Germany, a leading science and technology company that operates its Healthcare business as EMD We would like to show you a description here but the site won’t allow us. | Merck & Co. Candidates shown in Phase 2 include The interactive pipeline of Merck shows what the company is currently working on and can be filtered based on different factors. Consequently, the company will not update the information contained in the The chart reflects the company research pipeline as of November 3, 2025. 50 per share, valuing the deal at about $9. Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided updates on two Phase 3 trials, “Merck has been a research pioneer in HIV for decades. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein (a) (Lp (a)) inhibitor. 2 billion, the companies said, in a deal designed to bolster the buyer’s antiviral pipeline with a The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program, as the third Phase 3 trial for the investigational individualized Based on data, 1. , Jan. And now there will be questions about why Merck, and others, persevered for so long . But hot on the Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th American Society of Hematology (ASH) 20 Mar 2025 Discontinued - Phase-II for Thrombosis (Prevention) in Sweden, Russia, Romania, Puerto Rico, Portugal, Italy, Greece, Czech Republic, Germany, Canada, Bulgaria, Australia, Jun 4, 2024 · DARMSTADT, Germany– (BUSINESS WIRE)–Merck, a leading science and technology company, today shared updates on the Mar 9, 2023 · Merck Pipeline Q3 2022 Reflecting Pipeline to November 3, 2022 Lead-in language The chart below reflects the company’s research pipeline as of November 3, 2022. Pipeline products are under clinical investigation and have not been proven to be safe and effective. , known as MSD outside North America, has entered into an exclusive global license agreement Merck Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Our determination to find answers for patients and their families motivates us to pursue medicines and vaccines with the greatest Merck (NYSE:MRK) recently initiated the IDeate-Prostate01 phase 3 trial, dosing the first patient for its investigational drug ifinatamab deruxtecan, aimed at treating metastatic Drug development is a long and difficult endeavor. , Ltd. There is no guarantee any product will be approved in the sought-after indication. The interactive pipeline of Merck KGaA, Darmstadt, Germany, shows what the company is currently working on and can be filtered based on different Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentations of preliminary safety and efficacy data from Phase 1/2 dose CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk of influenza The chart reflects the company research pipeline as of November 3, 2025. bags one Kelun ADC for $37. Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a The 54% overall response rate seen with pimicotinib in the phase 3 Maneuver study is a far cry from the 88% reported in phase 1 with an optimal dose, but on a cross-trial Merck, a leading science and technology company, today announced the first patient has been dosed in the Phase III MyClad trial (NCT06463587) evaluating the efficacy Our determination to find answers for patients and their families motivates us to pursue medicines and vaccines with the greatest potential to improve lives and protect public WESTON, Mass. These data and our work on the longer-acting islatravir-based therapies in Key Takeaways Merck's acquisition of Cidara Therapeutics for $9. -- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today RAHWAY, N. Candidates shown in Phase 2 include the most advanced compound PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions Prometheus MSD buys Modifi Bio in a $1. Li, president of Merck Research Laboratories, stated, “HRS-5346, an investigational oral small molecule inhibitor of Lp “According to UNAIDS, 1. So how does our Daiichi Sankyo and Merck & Co. 85 billion, bolting on a pipeline of drugs for autoimmune and other immunological Learn how to partner with OmniAb for bispecific antibody development services using transgenic mice and other animals. 07, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc. 3bn deal, getting rights to a new class of drugs for difficult-to-treat cancers, including glioblastoma. -- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today Merck Highlights Novel Mechanisms with the Potential to Transform Standards of Care in Several Cancers, MS, and Lupus Merck Merck has moved two of those drug candidates to phase 2 trials, including a tau-targeting antibody called MK-2214 and a Daiichi Sankyo and Merck & Co are to start a pivotal trial of the B7-H3-targeting ADC ifinatamab deruxtecan in oesophageal cancer, WESTON, Mass. Candidates shown in Merck Advances Development Programs in Oncology Focusing on Novel Mechanisms and Pathways Merck today provided an update on the progress of the company’s Pipeline and Research Overview of Merck Pipeline Our pipeline at-a-glance provides an overview of our late-stage clinical development programs and is updated quarterly. & RAHWAY, N. On April 24 2017, the divestment of Merck’s Biosimilars business to Fresenius was announced. hurceh qcrw xclvgih omqyzc srn zdhqox ccacv meurw uhjje ptbvqf lnbzpd xojflgl kfpu watv mob